CatalogHepatitis C
NATDAC 60
Daclatasvir 60 mg
- Active ingredient
- Daclatasvir 60 mg
- Brand
- Natco Pharma
- Category
- Hepatitis C
About the active ingredient
Based on EMA information for Daklinza, not the manufacturer’s leaflet for NATDAC 60.
Use
Daclatasvir is used in combination treatment of hepatitis C, not as monotherapy.
Adverse effects
Headache, fatigue and nausea occur with sofosbuvir combinations. Additional medicines change the adverse-effect profile.
Interactions and restrictions
Interactions can substantially change daclatasvir exposure. The reference leaflet lists incompatible combinations, including rifampicin and St John’s wort; dosing cannot be copied from another regimen.
Storage and expiry
Use the storage instructions and expiry printed on your batch and its leaflet. Solutions may have additional requirements after opening or preparation.
Daklinza product information (PDF, English) · EMA overview
Sources checked 16 September 2026